Table 2 Characteristics of the study population of the five-year period.
From: Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland
All children N = 159 172 | Age groups | |||||
|---|---|---|---|---|---|---|
<1 year | 1 year | 2–4 years | 5–10 years | 11–17 years | ||
N = 8 607 | N = 17 602 | N = 45 104 | N = 92 111 | N = 95 686 | ||
Children | Number of children [N, %] | |||||
Male | 81 850, 51.4 | 4 459, 51.8 | 9 025, 51.3 | 23 141, 51.3 | 47 404, 51.5 | 49 240, 51.5 |
Female | 77 322, 48.6 | 4 148, 48.2 | 8 577, 48.7 | 21 963, 48.7 | 44 707, 48.5 | 46 446, 48.5 |
Children with drug claims | ||||||
Any drug | 151 632, 95.3 | 7 790, 90.5 | 17 296, 98.3 | 41 764, 92.6 | 81 906, 88.9 | 84 324, 88.1 |
≥1 PGx drugs | 105 192, 66.1 | 1 064, 12.4 | 8 516, 48.4 | 27 328, 60.6 | 50 153, 54.4 | 48 543, 50.7 |
≥2 PGx drugs | 35 396, 22.2 | 72, 0.8 | 911, 5.2 | 5 920, 13.1 | 12 991, 14.1 | 14 894, 15.6 |
≥3 PGx drugs | 9 231, 5.8 | 7, 0.1 | 74, 0.4 | 1 009, 2.2 | 2 803, 3.0 | 4 195, 4.4 |
≥4 PGx drugs | 2 319, 1.5 | 1, <0.1 | 8, <0.1 | 147, 0.3 | 672, 0.7 | 1 181, 1.2 |
≥5 PGx drugs | 487, 0.3 | 0, 0.0 | 0, 0.0 | 19, <0.1 | 110, 0.1 | 290, 0.3 |
≥10 PGx drugs | 3, <0.1 | 0, 0.0 | 0, 0.0 | 0, 0.0 | 0, 0.0 | 3, <0.1 |
≥1 syst PGx drugs | 100 249, 63.0 | 926, 10.8 | 8 159, 46.4 | 26 255, 58.2 | 46 881, 50.9 | 46 002, 48.1 |
≥1 PGx drug excl. ibuprofen | 44 815, 28.2 | 296, 3.4 | 1 506, 8.6 | 7 847, 17.4 | 17 884, 19.4 | 20 863, 21.8 |
≥1 syst PGx drug excl. ibuprofen | 28 976, 18.2 | 125, 1.5 | 708, 4.0 | 4 597, 10.2 | 9 391, 10.2 | 15 707, 16.4 |
≥2 syst PGx drug excl. ibuprofen | 6 438, 4.0 | 4, <0.1 | 49, 0.3 | 642, 1.4 | 1 793, 1.9 | 3 772, 3.9 |
≥3 syst PGx drug excl. ibuprofen | 1 604, 1.0 | 1, <0.1 | 2, <0.1 | 110, 0.2 | 409, 0.4 | 1 008, 1.1 |
Mean number of (PGx) drugs per child ± sd | ||||||
Drugs | 10.7 ± 8.0 | 4.9 ± 3.3 | 8.2 ± 4.2 | 8.0 ± 6.3 | 6.7 ± 6.2 | 7.6 ± 7.4 |
PGx drugs | 1.0 ± 0.9 | 0.1 ± 0.4 | 0.5 ± 0.6 | 0.8 ± 0.7 | 0.7 ± 0.8 | 0.7 ± 0.9 |
